{"id":"targeted-drug","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Rash"},{"rate":"20-40%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The drug specifically targets a protein that is overexpressed in certain types of cancer, leading to the inhibition of tumor growth and metastasis. This targeted approach aims to minimize harm to healthy cells while maximizing the impact on cancer cells.","oneSentence":"This targeted drug works by binding to a specific protein on cancer cells, preventing them from growing and dividing.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:36.455Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, EGFR mutation positive"},{"name":"Head and neck cancer, EGFR mutation positive"}]},"trialDetails":[{"nctId":"NCT06385483","phase":"PHASE2","title":"Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-28","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma","enrollment":19},{"nctId":"NCT07496632","phase":"NA","title":"Effect of Scalp Block on Intraoperative Hemodynamics and Postoperative Pain in Craniotomy Patients\"","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Medical University","startDate":"2026-04","conditions":"Scalp Block","enrollment":72},{"nctId":"NCT04040634","phase":"NA","title":"Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital Israelita Albert Einstein","startDate":"2019-08-08","conditions":"Diabetes Mellitus, High Blood Pressure, Cardiovascular Diseases","enrollment":9476},{"nctId":"NCT07281638","phase":"NA","title":"Bedside Bike Early Mobilization Program for Inpatients","status":"NOT_YET_RECRUITING","sponsor":"Indiana University","startDate":"2026-07-05","conditions":"Immobility Syndrome, Deep Venous Thrombosis, Delirium","enrollment":80},{"nctId":"NCT07498374","phase":"NA","title":"Efficacy and Safety of Fully Resorbable Sinus Drug-eluting Stents in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps After Surgery: A Prospective, Randomized Controlled Trial","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2026-01-21","conditions":"Eosinophilic Chronic Rhinosinusitis With Nasal Polyps","enrollment":192},{"nctId":"NCT06982222","phase":"PHASE1","title":"Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-31","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma","enrollment":24},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT07444814","phase":"PHASE1","title":"Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Whitehawk Therapeutics, Inc.","startDate":"2025-12-19","conditions":"Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic","enrollment":226},{"nctId":"NCT07489287","phase":"PHASE1","title":"GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer","status":"NOT_YET_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-06-15","conditions":"Platinum-resistant Ovarian Cancer","enrollment":18},{"nctId":"NCT01306019","phase":"PHASE1, PHASE2","title":"Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-09-25","conditions":"X-linked Severe Combined Immunodeficiency (XSCID)","enrollment":40},{"nctId":"NCT04531046","phase":"PHASE2","title":"Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2021-03-10","conditions":"B-Cell Lymphoma Refractory, B-cell Lymphoma Recurrent","enrollment":62},{"nctId":"NCT03109288","phase":"PHASE1, PHASE2","title":"Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-08-11","conditions":"Multiple Sclerosis","enrollment":250},{"nctId":"NCT06802523","phase":"PHASE1","title":"Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-21","conditions":"Acute Myeloid Leukemia","enrollment":53},{"nctId":"NCT05538130","phase":"PHASE1","title":"A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-11-30","conditions":"Melanoma, Glioma, Thyroid Cancer","enrollment":124},{"nctId":"NCT03297606","phase":"PHASE2","title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-03-23","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":720},{"nctId":"NCT04871139","phase":"NA","title":"An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-04-08","conditions":"Breast Carcinoma","enrollment":100},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT07497399","phase":"PHASE2","title":"Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-04","conditions":"Multiple Sclerosis","enrollment":120},{"nctId":"NCT05691517","phase":"PHASE1","title":"Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-12","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":35},{"nctId":"NCT04167969","phase":"PHASE1","title":"The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-02-17","conditions":"Prostate Cancer","enrollment":16},{"nctId":"NCT05904080","phase":"PHASE2","title":"Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-19","conditions":"Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8","enrollment":50},{"nctId":"NCT03752034","phase":"NA","title":"Muscle Fiber Fragments for Improved Function of Rotator Cuff Musculature Following Rotator Cuff Repair","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2019-11-04","conditions":"Rotator Cuff","enrollment":20},{"nctId":"NCT05674240","phase":"","title":"Prospective Evaluation of Intrathecal Targeted Drug Delivery for Cancer Associated Pain","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2022-12-06","conditions":"Cancer Pain, Chronic Pain, Cancer Associated Pain","enrollment":30},{"nctId":"NCT03866382","phase":"PHASE2","title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-13","conditions":"Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma","enrollment":314},{"nctId":"NCT06959771","phase":"PHASE1, PHASE2","title":"Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-07-16","conditions":"CD40L-HyperIgM Syndrome","enrollment":1},{"nctId":"NCT06390826","phase":"PHASE2","title":"Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-11-01","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma","enrollment":10},{"nctId":"NCT07340554","phase":"NA","title":"Neuroimaging of Adolescent Cannabis Use Treatment","status":"RECRUITING","sponsor":"Indiana University","startDate":"2026-04","conditions":"Cannabis Use, Cannabis Dependence, Cannabis Use Disorder","enrollment":80},{"nctId":"NCT07288034","phase":"PHASE2","title":"Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-09-21","conditions":"Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8","enrollment":535},{"nctId":"NCT04826341","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-09-20","conditions":"HRD Cancer, SCLC, Advanced Solid Tumors","enrollment":120},{"nctId":"NCT07328490","phase":"PHASE1, PHASE2","title":"Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Small Cell Carcinoma","enrollment":120},{"nctId":"NCT05724108","phase":"PHASE2","title":"Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-30","conditions":"Metastatic Neuroendocrine Tumor","enrollment":94},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT03173937","phase":"PHASE1, PHASE2","title":"Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2017-06-13","conditions":"Severe Aplastic Anemia, Hypo-Plastic MDS, Myelodysplastic Syndrome (MDS)","enrollment":37},{"nctId":"NCT07228065","phase":"NA","title":"Fixed-Dose Combinations Pragmatic Randomized Implementation Trial for Blood Pressure Control","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-05-01","conditions":"Hypertension, Primary Care","enrollment":720},{"nctId":"NCT05673200","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-09-25","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":32},{"nctId":"NCT06630806","phase":"PHASE1","title":"A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-10-30","conditions":"Plasma Cell Myeloma Refractory","enrollment":87},{"nctId":"NCT07491991","phase":"PHASE4","title":"Effects of Different Drugs for Glottic Atomization on Postoperative Sore Throat After Thyroid Surgery","status":"COMPLETED","sponsor":"Qianfoshan Hospital","startDate":"2025-03-02","conditions":"Postoperative Pain, NEBULIZATION, Thyroid Surgery","enrollment":96},{"nctId":"NCT07492914","phase":"PHASE2","title":"Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-03-20","conditions":"Resected Head and Neck Cancer","enrollment":30},{"nctId":"NCT06365853","phase":"PHASE2","title":"A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-07-29","conditions":"Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive","enrollment":100},{"nctId":"NCT06524232","phase":"NA","title":"The STop UNhealthy Substance Use Now Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2024-09-16","conditions":"Risky Health Behavior, Substance Use Disorders, Substance Abuse","enrollment":144},{"nctId":"NCT07488611","phase":"PHASE3","title":"PROGAIN Trial in Gastric Cancer Surgery","status":"RECRUITING","sponsor":"Soonchunhyang University Hospital","startDate":"2026-02-13","conditions":"Stomach (Gastric) Cancer","enrollment":100},{"nctId":"NCT07179614","phase":"NA","title":"Kentucky Women's Justice Community Overdose Innovation Network - Phase II","status":"NOT_YET_RECRUITING","sponsor":"Michele Staton","startDate":"2026-04-15","conditions":"Overdose Risk, Opioid Use Disorder, Stimulant Use Disorders","enrollment":300},{"nctId":"NCT07493655","phase":"NA","title":"Therapeutic Drug Monitoring of Mycophenolate Mofetil in Lupus Nephritis","status":"NOT_YET_RECRUITING","sponsor":"Federal University of Maranhao","startDate":"2026-07-01","conditions":"Systemic Lupus Erythematosus, Lupus Nephritis, Drug Monitoring","enrollment":100},{"nctId":"NCT06657261","phase":"NA","title":"Comparison of the Analgesic Efficacy of Chest Wall Blocks in Coronary Artery Bypass Surgery","status":"COMPLETED","sponsor":"Ankara City Hospital Bilkent","startDate":"2024-05-01","conditions":"Coronary Arterial Disease (CAD), Serratus Anterior Muscle Plane Block, Transversus Thoracis Muscle Plane Block","enrollment":60},{"nctId":"NCT07493395","phase":"PHASE2","title":"Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2026-04-01","conditions":"Scleroderma, Systemic","enrollment":6},{"nctId":"NCT05395741","phase":"PHASE1, PHASE2","title":"Regorafenib in Patients With Refractory Primary Bone Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Mother and Child, Warsaw, Poland","startDate":"2022-04-28","conditions":"Osteosarcoma, Ewing Sarcoma of Bone","enrollment":30},{"nctId":"NCT05688410","phase":"NA","title":"Enhancing Exercise and Psychotherapy to Treat Pain and Addiction in Adults With an Opioid Use Disorder (EXPO; R33 Phase)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Case Western Reserve University","startDate":"2023-02-10","conditions":"Opioid Use Disorder, Pain","enrollment":198},{"nctId":"NCT04736550","phase":"NA","title":"Enhancing Exercise and Psychotherapy to Treat Pain and Addiction in Opioid Use Disorders (\"EXPO\" Pilot Trial)","status":"COMPLETED","sponsor":"Case Western Reserve University","startDate":"2021-01-08","conditions":"Opioid-use Disorder, Pain","enrollment":63},{"nctId":"NCT07490275","phase":"PHASE1","title":"Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Refractory/Relapsed Systemic Lupus Erythematosus, Refractory / Relapsed / Progressive Systemic Sclerosis, Refractory / Relapsing / Progressive Inflammatory Myopathy","enrollment":9},{"nctId":"NCT07250269","phase":"PHASE1","title":"Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis","status":"RECRUITING","sponsor":"Gracell Biotechnologies (Shanghai) Co., Ltd.","startDate":"2025-10-29","conditions":"Relapsed/Refractory AL Amyloidosis","enrollment":9},{"nctId":"NCT07490951","phase":"NA","title":"Cluster of Differentiation 19 (CD19)/B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Refractory Autoimmune Diseases","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Genocury Biotech Co., Ltd.","startDate":"2026-03-22","conditions":"Autoimmune Diseases","enrollment":20},{"nctId":"NCT07489677","phase":"NA","title":"The Feasibility and Acceptability of a Collaborative Deprescribing Intervention to Reduce Anticholinergic Burden Among Hospitalised Older Patients","status":"COMPLETED","sponsor":"University Hospital Southampton NHS Foundation Trust","startDate":"2025-05-22","conditions":"Older Adults (60 - 85 Years Old)","enrollment":21},{"nctId":"NCT04189614","phase":"PHASE1","title":"An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-02-13","conditions":"Cancer, Non-small Cell Lung Cancer (NSCLC)","enrollment":65},{"nctId":"NCT01445509","phase":"PHASE1","title":"Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-12-29","conditions":"Solid Tumors","enrollment":50},{"nctId":"NCT06325709","phase":"PHASE1, PHASE2","title":"Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-04-17","conditions":"Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease","enrollment":10},{"nctId":"NCT05413304","phase":"PHASE1","title":"Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-07","conditions":"Glioma","enrollment":1},{"nctId":"NCT06465069","phase":"PHASE1","title":"A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-07-01","conditions":"Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor","enrollment":420},{"nctId":"NCT05046171","phase":"PHASE1, PHASE2","title":"Decreasing Polypharmacy in Older Adults With Curable Cancers Trial","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2022-06-14","conditions":"Cancer","enrollment":51},{"nctId":"NCT07490522","phase":"NA","title":"The Remote Monitoring of Gout Feasibility Study in Primary Care","status":"NOT_YET_RECRUITING","sponsor":"Diakonhjemmet Hospital","startDate":"2026-04","conditions":"Gout","enrollment":50},{"nctId":"NCT04990323","phase":"PHASE1, PHASE2","title":"US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies","status":"COMPLETED","sponsor":"ExCellThera inc.","startDate":"2021-12-01","conditions":"High Risk Myeloid Malignancies, Cord Blood Transplant","enrollment":13},{"nctId":"NCT07489326","phase":"","title":"The SetPoint System Safety & Performance Post-Approval Study","status":"NOT_YET_RECRUITING","sponsor":"SetPoint Medical Corporation","startDate":"2026-04-15","conditions":"Rheumatoid Arthritis","enrollment":150},{"nctId":"NCT07426094","phase":"PHASE2, PHASE3","title":"PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer","status":"RECRUITING","sponsor":"Affidea Nu-med Center of Oncological DIagnostics and Therapy","startDate":"2026-03-19","conditions":"Prostate Cancer, Brachytherapy, Stereotactic Body Radiation Therapy (SBRT)","enrollment":1600},{"nctId":"NCT06821542","phase":"PHASE3","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-04","conditions":"Chronic Graft-versus-host-disease","enrollment":9},{"nctId":"NCT07011342","phase":"NA","title":"Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2025-10-01","conditions":"Prostate Cancer","enrollment":70},{"nctId":"NCT04266249","phase":"PHASE2","title":"CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-03-13","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8","enrollment":2175},{"nctId":"NCT07392957","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-04-30","conditions":"Glioblastoma","enrollment":54},{"nctId":"NCT07426055","phase":"PHASE2, PHASE3","title":"PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer","status":"RECRUITING","sponsor":"Affidea Nu-med Center of Oncological DIagnostics and Therapy","startDate":"2026-03-19","conditions":"Prostate Cancer (Adenocarcinoma), Prostate Brachytherapy, Stereotactic Body Radiation Therapy (SBRT)","enrollment":1200},{"nctId":"NCT07417124","phase":"PHASE1","title":"Assess the Safety and Tolerability of SNS851 in Healthy Participants","status":"RECRUITING","sponsor":"Oneness Biotech Co., Ltd.","startDate":"2026-03","conditions":"Metabolic Disease","enrollment":52},{"nctId":"NCT07487597","phase":"EARLY_PHASE1","title":"Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors","status":"RECRUITING","sponsor":"TCRCure Biopharma Ltd.","startDate":"2026-02-28","conditions":"Solid Tumor","enrollment":24},{"nctId":"NCT07488572","phase":"PHASE2","title":"Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study","status":"ENROLLING_BY_INVITATION","sponsor":"Sun Yat-sen University","startDate":"2025-11-01","conditions":"Renal Cell Carcinoma (RCC), Metastatic Clear Cell Renal Cell Carcinoma","enrollment":60},{"nctId":"NCT06789081","phase":"EARLY_PHASE1","title":"GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2024-02-01","conditions":"Alveolar Soft Part Sarcoma","enrollment":1},{"nctId":"NCT07485842","phase":"PHASE4","title":"FuKe Qianjin Capsule Plus Antibiotics for Chronic Endometritis","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University","startDate":"2026-04","conditions":"Chronic Endometritis","enrollment":300},{"nctId":"NCT06738160","phase":"PHASE2","title":"The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-02-15","conditions":"NSCLC, Stereotactic Body Radiation Therapy (SBRT), Immunotherapy","enrollment":27},{"nctId":"NCT06641908","phase":"PHASE1","title":"Anti-GD2 ADC M3554 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2024-11-08","conditions":"Advanced Solid Tumor","enrollment":52},{"nctId":"NCT03796156","phase":"PHASE3","title":"Aspirin to Target Arterial Events in Chronic Kidney Disease","status":"TERMINATED","sponsor":"University of Southampton","startDate":"2019-02-25","conditions":"Chronic Kidney Diseases, Cardiovascular Diseases, Bleeding","enrollment":4633},{"nctId":"NCT07124078","phase":"PHASE2","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2026-03-31","conditions":"Chronic Graft-versus-host-disease","enrollment":60},{"nctId":"NCT05948865","phase":"PHASE1","title":"A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Conjupro Biotherapeutics, Inc.","startDate":"2023-06-06","conditions":"Cancer, Cancer, Lung","enrollment":132},{"nctId":"NCT06469957","phase":"","title":"Impact of Hospital Pharmacist on Drug Management in Patients With Bronchopulmonary Cancer","status":"COMPLETED","sponsor":"Centre Hospitalier Régional d'Orléans","startDate":"2024-06-25","conditions":"Patients With Bronchopulmonary Cancer","enrollment":60},{"nctId":"NCT05748171","phase":"PHASE2","title":"A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL","status":"RECRUITING","sponsor":"Pfizer","startDate":"2023-05-17","conditions":"ACUTE LYMPHOBLASTIC LEUKEMIA","enrollment":100},{"nctId":"NCT07380984","phase":"PHASE2","title":"PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2026-03","conditions":"Natural Killer/T-cell Lymphoma","enrollment":47},{"nctId":"NCT06842498","phase":"PHASE2","title":"A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"RECRUITING","sponsor":"Kyntra Bio","startDate":"2026-02-22","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":75},{"nctId":"NCT06158139","phase":"PHASE1","title":"Autologous CAR-T Cells Targeting B7-H3 in PDAC","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2024-07-18","conditions":"Pancreas Cancer, Relapse, Resistant Cancer","enrollment":27},{"nctId":"NCT04040829","phase":"NA","title":"Cognitive Remediation and Supported Education in Psychotic Disorders","status":"TERMINATED","sponsor":"Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec","startDate":"2021-09-01","conditions":"Psychotic Disorders","enrollment":9},{"nctId":"NCT04278768","phase":"PHASE1, PHASE2","title":"Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)","status":"SUSPENDED","sponsor":"Curis, Inc.","startDate":"2020-07-06","conditions":"Acute Myelogenous Leukemia, Myelodysplastic Syndrome","enrollment":366},{"nctId":"NCT03180216","phase":"PHASE1","title":"T-Lymphocytes for Prevention or Treatment of Viral Infections Following Hematopoietic Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's National Research Institute","startDate":"2017-02-15","conditions":"Viral Infections, Bone Marrow Transplant Infection","enrollment":32},{"nctId":"NCT05515354","phase":"PHASE4","title":"Smoking Cessation and Menstrual Cycle Phase","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2022-11-30","conditions":"Nicotine Dependence, Tobacco Smoking, Smoking Cessation","enrollment":1200},{"nctId":"NCT07169734","phase":"PHASE1, PHASE2","title":"A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors","status":"RECRUITING","sponsor":"Alentis Therapeutics AG","startDate":"2025-08-26","conditions":"Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer","enrollment":180},{"nctId":"NCT05776316","phase":"NA","title":"Harm Reduction Services","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2024-11-25","conditions":"Drug Use, Substance Abuse, Mental Illness","enrollment":200},{"nctId":"NCT07484022","phase":"PHASE1","title":"Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Generate Biomedicines","startDate":"2026-03","conditions":"Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma","enrollment":37},{"nctId":"NCT07350863","phase":"PHASE1","title":"U69-CART-Cells For R/R T-ALL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-06-25","conditions":"Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma","enrollment":12},{"nctId":"NCT05431192","phase":"NA","title":"Mind Your Heart-II","status":"RECRUITING","sponsor":"The Miriam Hospital","startDate":"2022-11-30","conditions":"Heart Failure, Cognitive Impairment","enrollment":176},{"nctId":"NCT02693535","phase":"PHASE2","title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","status":"RECRUITING","sponsor":"American Society of Clinical Oncology","startDate":"2016-03-14","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":4200},{"nctId":"NCT06357975","phase":"PHASE2","title":"Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-07-29","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma","enrollment":44},{"nctId":"NCT07483112","phase":"NA","title":"Fiber-Boost Randomized Controlled Trial","status":"RECRUITING","sponsor":"Cantonal Hospital of St. Gallen","startDate":"2025-10-07","conditions":"Non-Small Cell Carcinoma of Lung","enrollment":42},{"nctId":"NCT04910568","phase":"PHASE1","title":"A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2021-07-26","conditions":"Multiple Myeloma","enrollment":126},{"nctId":"NCT05529927","phase":"PHASE2","title":"Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Parnassia Addiction Research Centre","startDate":"2026-05","conditions":"Cocaine Use Disorder","enrollment":204},{"nctId":"NCT06708455","phase":"PHASE2","title":"Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Rapa Therapeutics LLC","startDate":"2027-03-01","conditions":"Malignant Melanoma With Metastasis, Malignant Melanoma, Malignant Melanoma Stage IIIc","enrollment":65},{"nctId":"NCT06045754","phase":"PHASE4","title":"A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-04-18","conditions":"Crohn's Disease","enrollment":100},{"nctId":"NCT07480954","phase":"PHASE1, PHASE2","title":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-04","conditions":"Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma","enrollment":36},{"nctId":"NCT06233942","phase":"PHASE1","title":"Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2024-04-12","conditions":"Advanced Solid Tumor","enrollment":308}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16173,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"targeted drug","genericName":"targeted drug","companyName":"Nanfang Hospital, Southern Medical University","companyId":"nanfang-hospital-southern-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Macimorelin is a small molecule used in research studies for conditions such as Growth Hormone Deficiency, Pain Threshold, and postoperative pain. It has been studied in combination with other interventions like Arginine and Clonidine in clinical trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}